Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
On July 6, 2020, Johnson & Johnson (NYSE: JNJ) partnered with the Stop TB Partnership, Global Fund, and USAID to enhance access to SIRTURO® (bedaquiline) for low- and middle-income countries. The company reduces the price to USD$340 per six-month treatment, supporting over 135 countries. Free goods will be provided based on order volume, potentially saving USD$16 million for national TB programs in the first year. This agreement aims to combat DR-TB amid the COVID-19 pandemic, aligning with WHO treatment guidelines.